Drug intelligence / Profile preview

TA8Amino

Development stage: Preclinical
Lead developer: Universidade Federal de Pelotas
Modality: Small Molecules

Overview

TA8Amino is a novel multi-target small molecule hybrid compound derived from donepezil and tacrine, designed for the treatment of Alzheimer's disease. It acts as a dual inhibitor of acetylcholinesterase (AChE) and Rho-associated protein kinase 2 (ROCK2). By inhibiting ROCK2, TA8Amino promotes neurogenesis through the activation of the PTEN/AKT signaling pathway, as demonstrated in SH-SY5Y neuroblastoma cells. Unlike its parent compounds, TA8Amino significantly reduces ROCK2 protein expression and increases neurite length and neurodifferentiation markers such as β-III-tubulin and MAP2.

Other names: donepezil-tacrine hybrid compound

Targets

AcetylcholinesteraseROCK2 (Rho-associated coiled-coil containing protein kinase 2)

Beyond the preview

Go deeper on TA8Amino.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TA8Amino.

Explore the full profile